Flores, Bill
U.S. Representative TX-17 Republican PartyCongressional stock trade history disclosed under the STOCK Act, as filed.
Latest disclosed trades
Latest 10 of 830| Ticker | Type | Traded |
|---|---|---|
| — salient MlP Fund [HN] F IlINg s | Sell | Dec 31, 2019 |
| SPN | Buy | Dec 19, 2019 |
| — Hyatt Hotels Corp Notes; 03/15/2 | Buy | Dec 6, 2019 |
| — salient MlP Fund, lP [HN] F IlIN | Sell | Nov 30, 2019 |
| IBM | Buy | Oct 2, 2019 |
| AVGO | Sell | Oct 2, 2019 |
| COP | Sell | Sep 19, 2019 |
| GILD | Buy | Sep 19, 2019 |
| LUV | Sell | Sep 19, 2019 |
| WBA | Buy | Sep 19, 2019 |
Amounts are reported as STOCK Act range buckets, not exact dollar values. Trade dates are the date the politician executed the trade; filing dates are when the disclosure was filed. Sign up to filter by ticker, amount range, or filing window.
Flores, Bill stock trade activity
FilingIQ has indexed 830 congressional stock trade disclosures for Flores, Bill. The most recent disclosed transaction is dated Dec 31, 2019.
Across the full history, 305 purchases and 524 sales have been disclosed under the STOCK Act.
Top tickers traded by Flores, Bill
Frequently asked
- How many stock trades has Flores, Bill disclosed?
- FilingIQ tracks 830 Periodic Transaction Report disclosures for Flores, Bill, with the most recent dated Dec 31, 2019. Every entry sources back to the official House Office of the Clerk or Senate Office of Public Records.
- Is Flores, Bill a net buyer or net seller?
- Across the disclosed trade history, 305 (37%) were purchases and 524 (63%) were sales. Compensation and exchanges are filtered out of these counts.
- Where does FilingIQ's data on Flores, Bill come from?
- Every trade shown on this page is sourced from the STOCK Act disclosures filed with the House or Senate. FilingIQ normalizes ticker resolution, dates, and amount brackets across both chambers.
Methodology & sources
Disclosures parsed from official House Office of the Clerk and Senate Office of Public Records filings. Methodology documented on methodology. Compiled by Thomas Kraaibeek. Not investment advice; see disclaimer.